Scottsdale Research Institute submits new ibogaine IND

Scottsdale Research Institute's new IND application

Scottsdale Research Institute has announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to study ibogaine, a psychoactive compound, for its potential in treating addiction. This move marks a significant step in exploring alternative treatments for substance use disorders.

Focus on addiction treatment

The institute aims to investigate ibogaine's efficacy and safety in addressing addiction, a growing public health concern. Ibogaine, derived from the root bark of the African shrub Tabernanthe iboga, has been studied for its potential to reduce withdrawal symptoms and cravings associated with opioid use disorder.

Regulatory context

Submitting an IND is a crucial step in the drug development process, allowing researchers to conduct clinical trials in the United States. The FDA's review will determine whether the proposed studies can proceed, based on the safety and scientific validity of the research plan.

Why it matters

With the opioid crisis continuing to impact communities across the U.S., finding effective treatments is more urgent than ever. Ibogaine's potential to offer a novel approach to addiction therapy could provide new hope for individuals struggling with substance use disorders.

Scottsdale Research Institute's initiative highlights the ongoing efforts to explore innovative solutions in addiction treatment.